FDA Authorizes Emalex Biosciences’ Expanded Access for Tourette Drug

Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy Receives FDA Authorization Emalex Biosciences, a clinical-stage biopharmaceutical company focused on developing innovative treatments for neurodevelopmental and neurological disorders, today announced a major development in its Tourette syndrome (TS) program.…

Read MoreFDA Authorizes Emalex Biosciences’ Expanded Access for Tourette Drug

ABRAT™-H Study Shows Targeted Interventions Reduce Violence in Hospital Patients

Groundbreaking ABRAT™-H Study Demonstrates Significant Reduction in Hospitalized Patient Violence, Reinforcing Efficacy of Proactive Risk Assessment Tools A landmark interventional study—the ABRAT™-H (Aggressive Behavior Risk Assessment Tool for Hospitalized Patients)—has yielded compelling evidence that structured screening combined with targeted interventions…

Read MoreABRAT™-H Study Shows Targeted Interventions Reduce Violence in Hospital Patients

HealthStream Acquires Virsys12 to Boost Credentialing for Payers

HealthStream Strengthens Payer-Focused Credentialing Capabilities with Strategic Acquisition of Virsys12 HealthStream (Nasdaq: HSTM), a nationally recognized leader in healthcare workforce development and technology solutions, has announced the strategic acquisition of Virsys12, a prominent healthcare technology company specializing in provider data…

Read MoreHealthStream Acquires Virsys12 to Boost Credentialing for Payers